Market News AIOpen the app

Recursion Pharmaceuticals, Inc. has signed a big deal for a stock sale to raise about $200 million.

New sharesRead the original at SEC EDGAR
Neutral

Recursion expects about $200 million from selling new shares and says its cash would fund work into 2029. The added time to fund its work comes with existing owners holding a smaller share, so the news points both ways.

RXRX · Recursion Pharmaceuticals, Inc.

AI read · Neutral

The AI's read

The added cash gives Recursion more time to pay for research and other costs. But it comes from selling new shares, leaving existing owners with a smaller share of the company. Recursion expects its cash to fund work into 2029, but the added time and reduced ownership point in different directions.

Get alerts for RXRX

Follow Recursion Pharmaceuticals, Inc. (RXRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RXRX
Free on the App Store and Google Play, or on the web.